近日，药明合联生物技术有限公司（“药明合联”）于香港交所主板成功上市，总募集资金约36.8亿港元（约4.7亿美元），成为今年迄今为止在香港的第三大IPO，以及最大医疗健康和生物科技IPO项目。

方达律师事务所、美国威尔逊律师事务所作为发行人律师参与交易；竞天公诚律师事务所、美国达维律师事务所则为承销商提供服务。

药明合联是药明生物和合全药业于2021年共同设立的合资公司，是生物偶联药CRDMO领域的龙头企业，其一站式生物偶联药物平台能够提供端对端CRDMO服务。路透社指出，今年全球范围内投资者对于生物科技板块的追逐引发了药明合联IPO的卓越表现。

该项目中，方达香港团队由合伙人罗德源、李一民牵头；境内团队由合伙人丁继栋、李娜、张浩和魏剑波牵头。

达维团队由全球合伙人褚洋、王薛林领导；

威尔逊公司法团队由合伙人陈炜恒、刘泳晖领导，税法团队由合伙人Myra A. Sutanto Shen领导。

WILSON SONSINI, DAVIS POLK, FANGDA, JINGTIAN ON $470 MLN WUXI XDC HONG KONG IPO

PRC law firm Fangda Partners and U.S. law firm Wilson Sonsini Goodrich & Rosati have advised Chinese medical research group WuXi XDC on its $470 million Hong Kong IPO, the third-largest new share sale in the city in 2023. Davis Polk & Wardwell and Jingtian & Gongcheng acted for the underwriters.

WuXi XDC is a joint venture between WuXi Biologics and WuXi STA that provides end-to-end contract research services covering antibodies and other biologics intermediates, Reuters reported. It added that investor interest in the biotech sector globally meant demand for WuXi XDC's IPO was among the strongest this year for a larger-sized deal in Hong Kong, where investor appetite for new share sales overall has been weak.

The Fangda team was led by partners Colin Law, Arman Lie, Jeffrey Ding, Diana Li, Hao Zhang and Jianbo Wei, while the Wilson Sonsini team was helmed by partners Weiheng Chen, Winfield Lau and Myra A. Sutanto Shen.

The Davis Polk team was headed by partners Yang Chu and Xuelin (Steve) Wang.